Hearing Loss, Mixed Conductive-Sensorineural

The new-gen Osia active bone conduction system, which comes with the Osia OSI300 Implant, is intended to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD) Osia Sound Processor and OSI300 Implant. (Credit: PRNewswire/Cochlear Limited) Australia-based implantable hearing solutions provider Cochlear has rolled out its next-generation Cochlear Osia System, which enables MRI scanning at 3 Tesla. Initially launched in 2020, the Osia System is an active osseointegrated bone conduction (OSI) bone conduction hearing solution that leverages digital piezoelectric stimulation. The new-gen Osia System is intended to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). It comes with the Osia OSI300 Implant and provides superior hearing outcomes, ease of use, discreetness and reliability. Cochlear said that the Osia System’s Piezo Power transducer, when combined with the next-gen implant magnet technology, enables the patient benefits. Also, it is the first and only active bone conduction system that enables MRI scans at both 1.5T and 3T without the need for surgery, said the Australian medical device maker. Cochlear intends to commercialise the next-gen Osia System across the US, with plans to extend it to other countries, subject to regulatory approvals. Cochlear portfolio strategy and professional marketing head Ryan Lopez said: “Not only does the new design allow for MRI scans at 3.0 T without surgery or the need for a headwrap or splint kit; we have also designed the magnet cassette to be simple to remove if needed. ”The easy removal of the implant magnet reduces image artifact, an important consideration for maximum visibility of areas around the implant. Both features mean less MRI preparation time and less time without sound, which is beneficial to both recipients and professionals.” According to Cochlear, axial magnets are used in most bone conduction implants and are unsuitable for a patient undergoing an MRI examination at 3T. Its OSI300 Implant is specifically designed to support MRI examination at 3T, with no performance degradation after MRI exposure. The implant leverages a diametric magnet, placed within a casing, and rotates to align with the magnetic field of the MRI machine. Cochlear said that it aims to help people with hearing implants undergo MRI scans without obstacles. Cochlear CEO and president Dig Howitt said: “An improvement in the ability of patients to undergo high-resolution MRI scans with our technology was the number one request we heard from customers. “With the new system, patients with an active bone conduction system can conveniently undergo MRI at 1.5T and at 3T with no impact to their hearing – MRI should be accessible to everyone.”

The new Osia® System with Osia OSI300 Implant enables patients to undergo MRI at 3.0 Tesla (T) without the need for surgery This has been made possible by the OSI300's unique Piezo Power™ technology and next-generation 3.0 T magnet technology The Osia System, which launched commercially in 2020, is indicated for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD) LONE TREE, Colo., Aug. 18, 2023 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). Continue Reading The new Osia® System with Osia OSI300 Implant enables patients to undergo MRI at 3.0 T without the need for surgery. Tweet this Osia Sound Processor and OSI300 Implant The new Osia System offers the proven benefits as the current version: excellent hearing outcomes1, ease of use, discreetness and reliability2. With the introduction of the OSI300 Implant, it is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery3. This new patient benefit is made possible by combining the unique properties of the Osia System's Piezo Power™ transducer, which does not contain magnetic material, and the next generation in implant magnet technology. The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure4, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants today and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine. "Not only does the new design allow for MRI scans at 3.0 T without surgery or the need for a headwrap or splint kit; we have also designed the magnet cassette to be simple to remove if needed. The easy removal of the implant magnet reduces image artifact, an important consideration for maximum visibility of areas around the implant. Both features mean less MRI preparation time and less time without sound, which is beneficial to both recipients and professionals," Ryan Lopez, Head of Portfolio Strategy & Professional Marketing at Cochlear, said. Today, most people can expect to undergo an MRI scan at some point in their lifetime and having a hearing implant shouldn't be an obstacle to this important healthcare treatment option. "The use of 3.0 T scanners is increasing and becoming more common. 3.0 T scanners help in the proper diagnosis of many neurologic, orthopedic and oncology conditions. It is important that patients don't face any obstacles to this type of care, and I am glad Cochlear has kept this in mind in their new Osia System," Dr. Brian Kaplan, SVP, Global Clinical Strategy & Innovation at Cochlear, Chairman of the Department of Otolaryngology, and Director of the Cochlear Implant Program at the Greater Baltimore Medical Center, said. Cochlear's product portfolio is inspired by meaningful innovation and a core belief that technology is only as useful as the benefit it provides. "An improvement in the ability of patients to undergo high-resolution MRI scans with our technology was the number one request we heard from customers. With the new system, patients with an active bone conduction system can conveniently undergo MRI at 1.5 T and at 3.0 T with no impact to their hearing – MRI should be accessible to everyone" says Dig Howitt, Chief Executive Officer & President of Cochlear. Launched commercially in 2020, the Osia System is the world's first active osseointegrated bone conduction (OSI), a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the inner ear (cochlea). Commercial release The next generation of the Osia System will be available in clinics across the United States this fall and is currently being reviewed by Health Canada. Availability in other countries is subject to regulatory approvals. For further information on the Osia System, visit cochlear.us/OsiaMRI-PR. About Cochlear Limited (ASX: COH) Cochlear is the global leader in implantable hearing solutions. The company has a global workforce of more than 4,000 people and invests more than AUD$180 million each year in research and development. Products include cochlear implants, bone conduction implants and acoustic implants, which healthcare professionals use to treat a range of moderate to profound types of hearing loss. Since 1981, Cochlear has provided more than 700,000 implantable devices, helping people of all ages, in more than 180 countries, to hear. References Mylanus EAM, Hua H, Wigren S, et al. Multicenter Clinical Investigation of a New Active Osseointegrated Steady-State Implant System. Otol Neurotol. 2020;41(9):1249-1257. OSI100 Implant and Osia Sound Processor;B P110 Power on Softband Osia Reliability Report Flyer, Cochlear Limited. 2023; D1841762. Ellsperman SE, Nairn EM, Stucken EZ. Review of Bone Conduction Hearing Devices. Audiol Res. 2021;11(2):207-219. Goh J. OSI200 Implant MRI Safety Verification Report. D1439962. Cochlear Bone Anchored Solutions AB, Sweden 2019 Cochlear, 科利耳, コクレア, 코클리어, Hear now. And always, Osia, SmartSound, the elliptical logo, and marks bearing an ® or ™ symbol, are either trademarks or registered trademarks of the Cochlear group of companies (unless otherwise noted). In the US, the Osia system is cleared for children 12 years and older. In Canada, the Osia system is approved for children 5 years of age and older. © Cochlear Limited 2023. All rights reserved. MEDIA RELEASE Christy LaPlante Cochlear Americas pr-cochlearamericas@cochlear.com SOURCE Cochlear Limited

DUBLIN--( BUSINESS WIRE )--The "Bone Anchored Hearing Aids Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global bone anchored hearing aids market size reached US$ 249 Million in 2021. Looking forward, the publisher expects the market to reach US$ 403 Million by 2027, exhibiting a CAGR of 8.36% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. A bone anchored hearing aid (BAHA) is a surgical, implantable device used to treat individuals with different types of hearing loss. It has a titanium screw anchored to the mastoid bone behind the ear, which is connected to a small detachable sound processor through an abutment that propagates sound directly to the inner ear, bypassing skin impedance and subcutaneous tissues. It provides better sound quality and greater comfort compared to conventional hearing devices. Compared to the BTE (behind-the-ear hearing aids), it does not cause skin irritation, requires less energy, reduces aural discharge, and is gaining traction worldwide among children and adults with single-sided deafness and conductive or mixed hearing loss. As the risk of developing hearing impairment increases with age, the rising geriatric population represents one of the key factors bolstering the market growth. Moreover, the growing instances of hearing loss in pediatrics, along with the high risk of surgery, are escalating the demand for soft band BAHA that acts as a non-surgical solution for a limited period. Additionally, governing agencies of several countries are implementing rules and regulations that require neonates to be screened for hearing loss. This trend, along with the availability of better reimbursement coverage, is impacting the market growth positively. Apart from this, robotic platforms and surgical navigation systems are gaining popularity around the world to reduce BAHA surgical complications. The market players are also introducing advanced products to expand their consumer base. For instance, MED-EL, a company that manufactures hearing implants, launched ADHEAR. This non-implanted BAHA device is suitable for all ages and provides effortless hearing and reliable listening. Key Market Segmentation: The publisher provides an analysis of the key trends in each sub-segment of the global bone anchored hearing aids market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on raw material, hearing loss type and end user. Breakup by Raw Material: Titanium Alloy Ceramics Composites Others Breakup by Hearing Loss Type: Sensorineural Hearing Loss Conductive Hearing Loss Mixed Hearing Loss Single Sided Deafness Breakup by End User: Pediatrics Adults Geriatrics Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 5 Global Bone Anchored Hearing Aids Market 6 Market Breakup by Raw Material 7 Market Breakup by Hearing Loss Type 8 Market Breakup by End User 9 Market Breakup by Region 10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis 13 Price Analysis 14 Competitive Landscape Companies Mentioned Auditdata A/S Cochlear Ltd. Demant A/S GN Hearing A/S (GN Store Nord A/S) Natus Medical Incorporated Sonova Holding AG Starkey Hearing Technologies Widex A/S. For more information about this report visit https://www.researchandmarkets.com/r/zdxhiv